Symjepi Generic Name & Formulations
Epinephrine 0.15mg, 0.3mg; per prefilled syringe; soln for IM or SC inj; contains sulfites.
Emergency treatment of allergic reactions (Type 1) including anaphylaxis.
Symjepi Dosage and Administration
Adults and Children
Give by IM or SC inj into the anterolateral aspect of the thigh only. 15–30kg: 0.15mg. ≥30kg: 0.3mg. May repeat another dose if needed.
Symjepi Boxed Warnings
The presence of sulfite in this product should not deter use. Cardiovascular disease. Hypertension. Hyperthyroidism. Diabetes. Parkinson’s disease. Injection-related complications: do not inject intravenously or into buttock (risk of Clostridium infection), digits, hands, or feet; hold leg firmly and limit movement in children prior to and during injection. Advise patient to seek medical help immediately. Train patient in use of device. Elderly. Pregnancy. Nursing mothers.
May be potentiated by MAOIs, tricyclic antidepressants, levothyroxine, antihistamines (eg, chlorpheniramine, tripelennamine, diphenhydramine). May be antagonized by β-blockers (eg, propranolol), α-blockers (eg, phentolamine), ergot alkaloids. Arrhythmias possible with cardiac glycosides, diuretics, or anti-arrhythmics.
Symjepi Adverse Reactions
Anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea, vomiting, headache, respiratory difficulties; arrhythmias, angina pectoris; rare: serious skin and soft tissue infections at inj site, stress cardiomyopathy.
Symjepi Clinical Trials
Symjepi Patient Counseling